2.Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy
Kyung Hwan KIM ; Chang Gon KIM ; Eui Cheol SHIN
Immune Network 2020;20(1):8-
Immune checkpoint blockade targeting PD-1 and PD-L1 has resulted in unprecedented clinical benefit for cancer patients. Anti-PD-1/PD-L1 therapy has become the standard treatment for diverse cancer types as monotherapy or in combination with other anti-cancer therapies, and its indications are expanding. However, many patients do not benefit from anti-PD-1/PD-L1 therapy due to primary and/or acquired resistance, which is a major obstacle to broadening the clinical applicability of anti-PD-1/PD-L1 therapy. In addition, hyperprogressive disease, an acceleration of tumor growth following anti-PD-1/PD-L1 therapy, has been proposed as a new response pattern associated with deleterious prognosis. Anti-PD-1/PD-L1 therapy can also cause a unique pattern of adverse events termed immune-related adverse events, sometimes leading to treatment discontinuation and fatal outcomes. Investigations have been carried out to predict and monitor treatment outcomes using peripheral blood as an alternative to tissue biopsy. This review summarizes recent studies utilizing peripheral blood immune cells to predict various outcomes in cancer patients treated with anti-PD-1/PD-L1 therapy.
Acceleration
;
Antigens, CD274
;
Biomarkers
;
Biopsy
;
Drug-Related Side Effects and Adverse Reactions
;
Fatal Outcome
;
Humans
;
Prognosis
;
Programmed Cell Death 1 Receptor
3.Analysis of
Yaping SHEN ; Kai YAN ; Minyue DONG ; Rulai YANG ; Xinwen HUANG
Journal of Zhejiang University. Medical sciences 2020;49(5):574-580
4.Clinical feature changes of a COVID-19 patient from mild to critical condition and cardiopulmonary pathological results.
Si Wei JIANG ; Hong GAO ; Lin WU ; Guo Wei WANG ; Fu Lan CEN ; Jin Xiu LI ; Cheng FENG ; Jun Min WEN ; Ye CHEN ; Ren Liang HE ; Kun QIAO ; Ying WANG ; Ying Xia LIU ; Zhao Qin WANG
Chinese Journal of Cardiology 2020;48(7):580-586
Objective: To analyse the clinical history, laboratory tests and pathological data of a patient who suffered from novel coronavirus pneumonia(COVID-19) and provide reference for the clinical treatment of similar cases. Methods: Data of clinical manifestation, laboratory examination, bronchoscopy, echocardiography and cardiopulmonary pathological results were retrospectively reviewed in a case of COVID-19 with rapid exacerbation from mild to critical condition. Results: This patient hospitalized at day 9 post 2019 novel coronavirus(2019-nCoV) infection, experienced progressive deterioration from mild to severe at day 12, severe to critical at day 18 and underwent extracorporeal membrane oxygenation(ECMO) and continuous renal replacement therapy(CRRT) as well as heart lung transplantation during day 28-45 post infection, and died at the second day post heart and lung transplantation. The patient had suffered from hypertension for 8 years. At the early stage of the disease, his symptoms were mild and the inflammatory indices increased and the lymphocyte count decreased continuously. The patient's condition exacerbated rapidly with multi-organ infections, and eventually developed pulmonary hemorrhage and consolidation, pulmonary hypertension, right heart failure, malignant ventricular arrhythmias, liver dysfunction, etc. His clinical manifestations could not be improved despite viral RNAs test results became negative. The patient underwent lung and heart transplantation and finally died of multi organ failure at the second day post lung and heart transplantation. Pathological examination indicated massive mucus, dark red secretions and blood clots in bronchus. The pathological changes were mainly diffused pulmonary hemorrhagic injuries and necrosis, fibrosis, small vessel disease with cardiac edema and lymphocyte infiltration. Conclusions: The clinical course of severe COVID-19 can exacerbate rapidly from mild to critical with lung, liver and heart injuries.
Betacoronavirus
;
COVID-19
;
Coronavirus Infections/pathology*
;
Fatal Outcome
;
Hemorrhage/virology*
;
Humans
;
Lung/pathology*
;
Myocardium/pathology*
;
Pandemics
;
Pneumonia, Viral/pathology*
;
Retrospective Studies
;
SARS-CoV-2
5.Pancreatic Cancer Presents as Inguinal Mass: A Case Report and Literature Review.
Chinese Medical Sciences Journal 2020;35(1):101-104
A 70-year-old male presenting with a mass in the right inguinal area was treated with surgery, and was diagnosed pathologically as spermatic cord metastasis of pancreatic cancer. He was given systemic chemotherapy. Unfortunately, he died of ascites and cachexia three months later.
Aged
;
Fatal Outcome
;
Genital Diseases, Male/surgery*
;
Humans
;
Male
;
Pancreatic Neoplasms/diagnostic imaging*
;
Spermatic Cord/surgery*
;
Tomography, X-Ray Computed/methods*
7.Variability of Platelet Reactivity on Antiplatelet Therapy in Neurointervention Procedure
Ho Jun YI ; Gyojun HWANG ; Byoung Hun LEE
Journal of Korean Neurosurgical Society 2019;62(1):3-9
As more intracranial aneurysms and other cerebrovascular pathologies are treated with neurointervention procedure, thromboembolic events that frequently lead to serious neurological deficit or fatal outcomes are increasing. In order to prevent the thromboembolic events, antiplatelet therapy is used in most procedures including coil embolization, stenting, and flow diversion. However, because of variable individual pharmacodynamics responses to antiplatelet drugs, especially clopidogrel, it is difficult for clinicians to select the adequate antiplatelet regimen and its optimal dose. This article reviews the neurointervention literature related to antiplatelet therapy and suggests a strategy for tailoring antiplatelet therapy in individual patients undergoing neurointervention based on the results of platelet function testing.
Aspirin
;
Blood Platelets
;
Embolization, Therapeutic
;
Fatal Outcome
;
Humans
;
Intracranial Aneurysm
;
Pathology
;
Platelet Aggregation Inhibitors
;
Platelet Function Tests
;
Stents
8.A case of telbivudine-related fatal lactic acidosis and multiple organ dysfunction syndrome.
Journal of Central South University(Medical Sciences) 2019;44(6):714-719
The incidence of telbivudine-related adverse reactions has been gradually increased. The increased levels of muscle enzymes and blood lactate are common. In this case, a 23-year-old male patient with long-term oral telbivudine had a rare serious adverse reaction. The main clinical manifestations were progressive myalgia, gradually progressed to mental disorder, and together with multiple organ dysfunction, in which the level of blood lactate was increased significantly and metabolic acidosis was extremely severe. Blood purification and sodium bicarbonate were given to correct acidosis, while ceftazidime was used to prevent infection. Telbivudine was discontinued, and tenofovir disoproxil fumarate and liver protective drug were used. The patient was discharged with a better health condition. Such patients are easily misdiagnosed as neuromuscular diseases in the early stage, which might delay the treatment and worsen medical conditions. Clinicians need to be cautious and obtain an early identification to avoid misdiagnosis.
Acidosis, Lactic
;
chemically induced
;
Fatal Outcome
;
Humans
;
Male
;
Multiple Organ Failure
;
Telbivudine
;
adverse effects
;
Young Adult
9.Molecular Mechanism and Progression of Primary Resistance to EGFR-TKI - Analysis of 2 Cases.
Meirong LIU ; Fanlu MENG ; Qing MA ; Liyan GU ; Diansheng ZHONG
Chinese Journal of Lung Cancer 2019;22(1):52-56
Tyrosine kinase inhibitor (TKI) have been proved to be effective in the treatment of advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) sensitive mutation, which is superior to chemotherapy. However, there are still some patients with sensitive mutations have primary drug resistance. It may be related to the coexistence of susceptible and resistant mutations of EGFR gene, downstream mutations of EGFR pathway, MET amplification and BIM deletion polymorphism. We present 2 cases of primary drug resistance and analyze the reasons.
.
Carcinoma, Non-Small-Cell Lung
;
diagnostic imaging
;
drug therapy
;
genetics
;
Disease Progression
;
Drug Resistance, Neoplasm
;
drug effects
;
genetics
;
ErbB Receptors
;
antagonists & inhibitors
;
genetics
;
Fatal Outcome
;
Humans
;
Lung Neoplasms
;
diagnostic imaging
;
drug therapy
;
genetics
;
Male
;
Middle Aged
;
Mutation
;
Protein Kinase Inhibitors
;
therapeutic use
;
Treatment Outcome
10.Massive Duodenal Bleeding after the Migration of Endovascular Coils into the Small Bowel
Chung Jo CHOI ; Hyun LIM ; Dong Suk KIM ; Yong Seol JEONG ; Sang Young PARK ; Jeong Eun KIM
Clinical Endoscopy 2019;52(6):612-615
Among gastrointestinal emergencies, acute upper gastrointestinal bleeding remains a challenging clinical problem owing to significant patient morbidity and costs involved in management. Endoscopic hemostatic therapy is the mainstay of treatment and decreases the incidence of re-bleeding, the need for surgery, morbidity, and mortality. However, in 8%–15% of patients with upper gastrointestinal bleeding, endoscopic hemostatic therapy does not successfully control bleeding. Trans-arterial coil embolization is an effective alternative treatment for endoscopic hemostatic failure; however, this procedure can induce adverse outcomes, such as non-target vessel occlusion, vessel dissection and perforation, and coil migration. Coil migration is rare but causes severe complications, such as re-bleeding and bowel ischemia. However, in most cases, coil migration is local and involves spontaneous healing without serious complications. Here, we report the case of a patient who underwent trans-arterial coil embolization of the gastroduodenal artery with the purpose of controlling massive duodenal bleeding, resulting in a fatal outcome caused by coil migration.
Arteries
;
Embolization, Therapeutic
;
Emergencies
;
Endoscopy
;
Fatal Outcome
;
Hemorrhage
;
Humans
;
Incidence
;
Ischemia
;
Mortality
;
Peptic Ulcer Hemorrhage

Result Analysis
Print
Save
E-mail